Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 6/2016

01-06-2016 | Original Contributions

How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery?

Authors: Rute M. Cerqueira, Manuel R. Correia, Hélder Vilar, M. Conceição Manso

Published in: Obesity Surgery | Issue 6/2016

Login to get access

Abstract

Aims and Methods

Our aim was to assess, in obese patients undergoing Roux-en Y gastric bypass surgery, the quadruple concomitant HP eradication rates at first line treatment as proposed by the Maastricht IV consensus in areas of high clarithromycin resistance rates—proton pump inhibitor bid, clarithromycin 500 mg bid, amoxicillin 1000 mg bid, and metronidazole 500 mg bid. This is a single center prospective study over a 3-year period. Endoscopy and HP assessment (by histology or C13 urea breath) were performed at baseline, and post treatment HP status was assessed by C13 urea breath test 4–6 weeks after the end of therapy.

Results

The study cohort consisted of 600 adult obese HP positive patients [19 % male/81 % female, age 40.7 (±10.4) years] consecutively scheduled for HP concomitant therapy. HP was eradicated in 416 patients [69.3 % (95% CI 65.5–72.9 %)] and the eradication was independent of gender, age, endoscopic diagnosis, and smoking status (p > 0.05).

Conclusions

Two weeks quadruple concomitant therapy did not achieve Maastricht recommended first line acceptable HP eradication rates (at least 80 %) in obese Portuguese patients undergoing GB.
Literature
1.
Quina M, Guerreiro A. Gastric cancer (carcinoma) and Helicobacter pylori: situation in Portugal. Hepato Gastroenterol. 2001;48:1565–8.
2.
Ferlay J, Autier P, Boniol M, et al. Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncology. 2007;18:581–92.CrossRef
3.
Cerqueira RM, Manso MC, Correia MR, et al. Helicobacter pylori eradication therapy in obese patients undergoing gastric by-pass surgery – fourteen days superior to seven days? Obes Surg. 2011;21(9):1377–81.CrossRefPubMed
4.
Watkins BJ, Blackmun S, Kuehner ME. Gastric adenocarcinoma after Roux-en-Y gastric bypass: access and evaluation of excluded stomach. Surg Obes Relat Dis. 2007;3:644–7.CrossRefPubMed
5.
Silechia G, Catalano C, Gentileschi P, et al. Virtual gastroduodenoscopy: a new look at the bypassed stomach and duodenum after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2002;12:339–48.CrossRef
6.
Gill KR, McKinney JM, Stark ME, et al. Investigation of the excluded stomach after Roux-en-Y gastric bypass: the role of percutaneous endoscopy. World J Gastroenterol. 2008;14:1946–8.CrossRefPubMedPubMedCentral
7.
Yamamoto H, Sekine Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointest Endosc. 2001;53:216–20.CrossRefPubMed
8.
Fried M, Hainer V, Basdevant A, et al. Inter-disciplinary European Guidelines on surgery of severe obesity. Int J Obes. 2007;31:569–77.
9.
ASGE Guidelines. Role of endoscopy in the bariatric patient. Gastrointest Endosc. 2008;68:1–10.CrossRef
10.
Orlando G, Pilone V, Vittiello A, et al. Gastric cancer following bariatric surgery. Surg Laparosc Endosc Percutan Tech. 2014;24:400–5.CrossRefPubMed
11.
Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–81.CrossRefPubMedPubMedCentral
12.
Malfertheiner P, Megraud F, O’Morain C, et al. Management of Helicobacter pylori infection—the Maastricht IV /Florence Consensus Report. Gut. 2012;61:646–64.CrossRefPubMed
13.
Cerqueira RM, Correia MR, Fernandes CD, et al. Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery. Obes Surg. 2013;23(2):145–8.CrossRefPubMed
14.
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–53.CrossRefPubMed
15.
Boyanova L. Prevalence of multi-drug resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009;58(Pt 7):930–5.CrossRefPubMed
16.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e 442.CrossRef
17.
18.
Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2010;8:36–41.CrossRefPubMedPubMedCentral
19.
Molina Infante J, Pazos Pacheco C, Vinagre Rodriguez G, et al. Non bismuth quadruple concomitant therapy versus standard triple therapy for clarithromycin susceptible H pylori and versus quadruple sequential therapy for clarithromycin resistant H pylori. Helicobacter. 2012;17(4):269–76.CrossRefPubMed
20.
Essa AS, Kramer JR, Graham DY, et al. Meta analysis: four drug, three antibiotic, non bismuth containing “concomitant therapy” versus triple therapy for Helicobacter pylori. Helicobacter. 2009;14:109–18.CrossRefPubMedPubMedCentral
21.
Gisbert P, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23–34.CrossRefPubMedPubMedCentral
22.
Greenberg ER, Anderson GL, Morgan DR, et al. 14 days triple, 5 days concomitant, and 10 days sequential therapies for Helicobacter pylori infection in seven Latin America sites: a randomised trial. Lancet. 2011;378:507–14.CrossRefPubMedPubMedCentral
23.
Toros AB, Ince AT, Kesis B, et al. A new modified concomitant therapy for Helicobacter pylori eradication in Turkey. Helicobater. 2011;16:225–8.CrossRef
24.
Zhu R, Chen K, Zheng YY, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. W J Gastroenterol. 2014;20:18013–21.
Metadata
Title
How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery?
Authors
Rute M. Cerqueira
Manuel R. Correia
Hélder Vilar
M. Conceição Manso
Publication date
01-06-2016
Publisher
Springer US
Published in
Obesity Surgery / Issue 6/2016
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-015-1920-3

Other articles of this Issue 6/2016

Obesity Surgery 6/2016 Go to the issue

Original Contributions

Monitoring of Diabetic Retinopathy in relation to Bariatric Surgery: a Prospective Observational Study

Original Contributions

Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease

Letter to the Editor

Gastric Band Removal in Revisional Bariatric Surgery: a One-Step or Two-Step Procedure?

Erratum

Erratum to: Mervyn Deitel—Biography

Original Contributions

Predictors of Excess Weight Loss in Obese Patients After Gastric Bypass: a 60-Month Follow-up

Letter to the Editor/LED Reply

Response to the Letter to the Editor—Re: Gastric Band Removal in Revisional Bariatric Surgery, One-Step Versus Two-Step: a Systematic Review and Meta-analysis